A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided Moderate or severe acute illness/infection (according to Investigator judgment) on the day of study intervention administration or febrile illness (temperature ≥ 100.4☏ ).Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion.Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination.Thrombocytopenia, contraindicating IM injection.Previous dermal filler injection (either lips or face fillers).Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances.Known or suspected congenital or acquired immunodeficiency or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the 3 months preceding planned inclusion).Able to attend all scheduled visits and to comply with all study procedures.Participants who previously received 2 injections of Moderna COVID-19 Vaccine with the second dose received at least 5 months before Visit 1.A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment In good health or with underlying medical condition(s) that are judged to be stable by the Investigator.Aged ≥ 65 years of age on the day of inclusion.
Why Should I Register and Submit Results?.
0 kommentar(er)
